ATE486892T1 - Verfahren zur kontrolle von krebs - Google Patents

Verfahren zur kontrolle von krebs

Info

Publication number
ATE486892T1
ATE486892T1 AT03794710T AT03794710T ATE486892T1 AT E486892 T1 ATE486892 T1 AT E486892T1 AT 03794710 T AT03794710 T AT 03794710T AT 03794710 T AT03794710 T AT 03794710T AT E486892 T1 ATE486892 T1 AT E486892T1
Authority
AT
Austria
Prior art keywords
cell
provides methods
ephb4
controlling cancer
cancerous growth
Prior art date
Application number
AT03794710T
Other languages
English (en)
Inventor
Sally-Anne Stephenson
Original Assignee
Queen Elizabeth Hospital Res F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Elizabeth Hospital Res F filed Critical Queen Elizabeth Hospital Res F
Application granted granted Critical
Publication of ATE486892T1 publication Critical patent/ATE486892T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT03794710T 2002-09-16 2003-09-16 Verfahren zur kontrolle von krebs ATE486892T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2002951409A AU2002951409A0 (en) 2002-09-16 2002-09-16 Methods for regulating cancer
PCT/AU2003/001209 WO2004024773A1 (en) 2002-09-16 2003-09-16 Methods for regulating cancer

Publications (1)

Publication Number Publication Date
ATE486892T1 true ATE486892T1 (de) 2010-11-15

Family

ID=27792678

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03794710T ATE486892T1 (de) 2002-09-16 2003-09-16 Verfahren zur kontrolle von krebs

Country Status (15)

Country Link
US (1) US7722866B2 (de)
EP (1) EP1546205B1 (de)
JP (1) JP4799863B2 (de)
KR (1) KR20050072744A (de)
CN (1) CN1694902B (de)
AT (1) ATE486892T1 (de)
AU (1) AU2002951409A0 (de)
BR (1) BR0314369A (de)
CA (1) CA2499130A1 (de)
DE (1) DE60334820D1 (de)
ES (1) ES2355503T3 (de)
MX (1) MXPA05002894A (de)
NZ (1) NZ539203A (de)
WO (1) WO2004024773A1 (de)
ZA (1) ZA200502863B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
AU2004220525B2 (en) 2003-03-12 2011-03-31 Vasgene Therapeutics, Inc. Nucleic acid compounds for inhibiting angiogenesis and tumor growth
DE602005025459D1 (de) * 2004-03-12 2011-02-03 Vasgene Therapeutics Inc Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
EP2275445A3 (de) * 2004-03-12 2012-02-29 Vasgene Therapeutics, Inc. Ephb4-bindende Antikörper zur Inhibierung von Angiogenese und Tumorwachstum
JP2008514925A (ja) * 2004-09-23 2008-05-08 バスジーン セラピューティクス， インコーポレイテッド 腫瘍を検出し且つ治療するための組成物及び方法
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
ZA200806053B (en) * 2006-01-05 2009-12-30 Genentech Inc Anti-EphB4 antibodies and methods using same
TWI391402B (zh) * 2006-01-05 2013-04-01 Genentech Inc 抗ｅｐｈｂ４抗體及使用該抗體之方法
AU2013200383B2 (en) * 2006-01-05 2016-05-12 Genentech,Inc. Anti-EphB4 antibodies and methods using same
CN103360496B (zh) 2006-01-05 2015-11-18 健泰科生物技术公司 抗ephb4抗体及其使用方法
DK2061510T3 (en) 2006-08-31 2016-09-05 A C N 135 493 391 Pty Ltd As Trustee For Conca Unit Trust Treatment and / or prevention of Barrett's esophagus using anti-EphB4 antibody-containing compositions
WO2008104803A2 (en) * 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
CN101932604A (zh) * 2007-03-12 2010-12-29 瓦斯基因治疗公司 EphB4作为诊断标记和作为卵巢癌的治疗靶标的用途
US20110009323A1 (en) * 2007-06-15 2011-01-13 Vasgene Therapeutics, Inc. Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth
CN102083861B (zh) 2007-08-13 2016-04-13 瓦斯基因治疗公司 使用结合EphB4的人源化抗体的癌症治疗
EP2492355B1 (de) * 2007-11-29 2015-04-08 MOLECULAR HEALTH GmbH Erythropoietin-Rezeptor zum Gewebeschutz und Verwendungsverfahren
US8357501B2 (en) 2007-11-29 2013-01-22 Molecular Health Gmbh Tissue protective erythropoietin receptor (NEPOR) and methods of use
AU2015204311B2 (en) * 2007-11-29 2017-06-08 Molecular Health Gmbh Novel tissue protective erythropoietin receptor (NEPOR) and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
EP1135153B1 (de) * 1998-11-20 2005-04-27 Genentech, Inc. Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
AU2002212292A1 (en) 2000-09-29 2002-04-08 Novartis Ag Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
EP1992643A3 (de) 2001-06-20 2008-12-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
AU2004220525B2 (en) * 2003-03-12 2011-03-31 Vasgene Therapeutics, Inc. Nucleic acid compounds for inhibiting angiogenesis and tumor growth

Also Published As

Publication number Publication date
BR0314369A (pt) 2005-08-09
WO2004024773A1 (en) 2004-03-25
NZ539203A (en) 2008-05-30
CA2499130A1 (en) 2004-03-25
ES2355503T3 (es) 2011-03-28
EP1546205B1 (de) 2010-11-03
CN1694902A (zh) 2005-11-09
US7722866B2 (en) 2010-05-25
KR20050072744A (ko) 2005-07-12
DE60334820D1 (de) 2010-12-16
CN1694902B (zh) 2012-10-10
ZA200502863B (en) 2006-06-28
AU2002951409A0 (en) 2002-09-26
JP4799863B2 (ja) 2011-10-26
EP1546205A1 (de) 2005-06-29
MXPA05002894A (es) 2005-10-05
US20060134118A1 (en) 2006-06-22
JP2006517906A (ja) 2006-08-03
EP1546205A4 (de) 2006-05-03

Similar Documents

Publication Publication Date Title
ATE486892T1 (de) Verfahren zur kontrolle von krebs
NO2017040I2 (no) Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC
DE69233791D1 (de) Verfahren zur Manipulation der Zelldifferenzierung
ATE464908T1 (de) Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
RS52769B (sr) Kompozicije i postupci za povećanje mineralizacije kostiju
DE602005017781D1 (de) Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür
CO5580797A2 (es) Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
DK1325033T3 (da) Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning
DE602006013029D1 (de) Anti-egfr-antikörper
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
DE602004023965D1 (de) Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
DE69932813D1 (de) Nukleinsäurebindungsproteine
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
EE200500012A (et) Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks
DE602004030041D1 (de) Verfahren und zusammensetzungen zur identifikation von rna-bindenden proteinen
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
ATE285418T1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
DE50307968D1 (de) Antikörper zur isolierung und/oder identifizierung mesenchymaler stammzellen und verfahren zur isolierung und/oder identifizierung mesenchymaler stammzellen
ATE312622T1 (de) Verwendung von anti-hbp antikörper zur inhibierung der freisetzung von bradykinin
DE602005025459D1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
MX2021014882A (es) Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties